Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The trajectory of racial/ethnic disparities in the use of cancer screening before and during the COVID-19 pandemic: A large U.S. academic center analysis

Felippe O. Marcondes a,c, David Cheng b, Erica T. Warner c, Sophia C. Kamran d, Jennifer S. Haas a,c,*

a Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, United States
b Division of Biostatistics, Massachusetts General Hospital, Boston, MA, United States
c Mongan Institute, Clinical Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA, United States
d Department of Radiation Oncology, Mass General Cancer Center, Massachusetts General Hospital, Boston, MA, United States

ARTICLE INFO

Keywords:
Cancer screening
Disparities
COVID-19

ABSTRACT

Cancer screening rates declined sharply early in the COVID-19 pandemic. The impact of the pandemic may have exacerbated existing disparities in cancer screening due to the disproportionate burden of illness and job loss among racial/ethnic minorities, and potentially, uneven resumption of care between different racial/ethnic groups. Using electronic health record data from Mass General Brigham (MGB), we assessed changes in rates of breast, cervical, colorectal and lung cancer screening before and during the pandemic. Among patients who received primary care in an MGB-affiliated primary care practice, cancer screening rates were calculated as the number of individuals who received a screening test for each cancer type over the number of individuals due for each test, during each month between April 2019–November 2020. We conducted an interrupted time-series analysis to test for changes in screening rates by race/ethnicity before and during the pandemic. Prior to the pandemic, relative to White individuals, Asian women were less likely to receive breast cancer screening (p < 0.001), and Latinx and Black individuals were less likely to screen for lung cancer (p < 0.001 and p = 0.02). Our results did not show significant improvement or worsening of racial/ethnic disparities for any cancer screening type as screening resumed. However, as of November 2020 rates of screening for breast cancer were lower than pre-pandemic levels for Latinx individuals, and lung cancer screening rates were higher than baseline for Latinx, Black or White individuals. Further monitoring of disparities in cancer screening is warranted as the pandemic evolves.

1. Introduction

Timely screening for breast, cervical, colorectal (CRC) and lung cancer reduces cancer morbidity and mortality and is endorsed by national guidelines for age-appropriate populations (Curry et al., 2018; Screening for Colorectal Cancer, 2008; Moyer, 2014; Siu, 2016). The timeliness of cancer screening becomes especially important during periods when the provision of care is constrained. Prior studies have shown that cancer screening deteriorates as a result of natural disasters and conflicts (Man et al., 2018; El Saghir et al., 2018; Nelson et al., 1997), and that delays in screening in these instances may result in higher stage of disease among those subsequently diagnosed with cancer (Kanjanvaikoon et al., 2011).

The COVID-19 pandemic presents challenges to the delivery of cancer screening. Cancer screening rates sharply declined in the U.S. early in the COVID-19 pandemic (Kaufman et al., 2020; Mast and Munoz del Rio, 2020; Corley et al., 2020; Miller et al., 2021). Concerns about preservation of personal protective equipment, avoidance of undue exposure to the virus in health care facilities, re-deployment of clinical staff, and government regulations affected cancer screening rates with many facilities closed for preventive services throughout Spring 2020. While COVID-19-related disruptions in care were widespread, the total burden of COVID-19 on cancer screening may not impact all groups equally, as racial/ethnic minorities have been disproportionately...
affected by the health, social, and economic consequences of the pandemic, and given the significant inequalities in cancer screening prior to the pandemic.

Racial and ethnic minorities in the US have experienced disparities in cancer screening, incidence and mortality. Latinx women have the highest incidence of cervical cancer, while non-Latinx Black (hereafter called Black) men and women have the highest cancer mortality of all racial and ethnic groups in the U.S. for lung, colorectal, breast, and cervical cancers, and for all cancers combined (U.S. Cancer Statistics Working Group, 2017). The observed disparities in cancer incidence and mortality reflect, in part, racial/ethnic disparities in the use of cancer screening. Black, Latinx and Asian individuals are also less likely to receive timely colorectal cancer screening (Beydoun and Beydoun, 2007). Latinx women are less likely to use mammography than non-Latinx White (hereafter called White) women (National Center for Health Statistics, 2019; White et al., 2017). For cervical cancer screening, the findings for Latinx and non-Latinx Asian (hereafter called Asian) women are mixed with some studies suggesting lower rates of timely screening compared to White women but others showing comparable or even higher rates (White et al., 2017; Chatterjee et al., 2016; Musselwhite et al., 2016; Hall et al., 2018). In summary, prior to the pandemic, racial/ethnic minorities were often less likely to receive timely breast, cervical, colorectal and lung cancer screening.

While the pandemic has highlighted the pre-pandemic disparities in health and health care in the U.S. and has fueled many new initiatives to promote health equity, concern remains that the COVID-19 pandemic may worsen racial/ethnic disparities in care, including the use of cancer screening (Corley et al., 2020), particularly since racial/ethnic minorities have been disproportionately affected by COVID-19 related illness, and may be more hesitant to accept the coronavirus vaccine (Kreps et al., 2020; COVID Collaborative, 2020).

The purpose of this study is to assess the trajectories of cancer screening by race/ethnicity before and during the initial period of the pandemic. Because COVID-19 has led to disproportionate illness and job loss among racial/ethnic minorities (Couch et al., 2020; Gold et al., 2020; Price-Haywood et al., 2020), we hypothesize that any disparities in cancer screening that were present before the pandemic have worsened over the course of 2020 as White individuals resumed their screening more quickly than Black, Latinx and Asian individuals.

2. Methods

2.1. Study design and population

This is a retrospective cohort study using electronic medical record data from Mass General Brigham (MGB), a large academic health system in eastern Massachusetts. To assess screening use in a population receiving primary care at MGB, individuals eligible for screening during each month of the study period were identified among those who had at least one visit to a primary care provider (PCP) in the prior 3 years relative to each month between April 1, 2019 and November 30, 2020. Because our focus was on screening use by race/ethnicity, we excluded racial/ethnic groups that were too small to analyze or had unknown race/ethnicity. To focus on individuals with average screening risk, we excluded individuals with prior cancer for each cancer type. For each month from April 2019 to November 2020, eligibility for screening was determined on a monthly basis by assessing whether a patient was alive at the beginning of the month and met cancer screening eligibility based on the United States Preventive Services Task Force (USPSTF) recommendations for each type of cancer screening test at the beginning of the month (Curry et al., 2018; Screening for Colorectal Cancer, 2008; Moyer, 2014; Siu, 2016), specifically: 1) For breast cancer screening, females 40–75 years of age without a documented mammogram, including digital breast tomosynthesis, in the previous two years; 2) For cervical cancer screening, females 21–65 years of age without a documented Pap test in the past 3 years; 3) For colorectal cancer screening, males and females 50–75 years of age without a colonoscopy in the past 10 years or a fecal immunohistochemistry test (FIT) in the past year; 4) For lung cancer screening, males and females age 55–80 years without a low dose computed tomography of the chest (LDCT) in the past year who currently smoke or quit smoking within the prior 15 years and the quit date was available. We did not include pack-years of smoking in our eligibility definition due to a high degree of missing data on smoking duration.

2.2. Study period

The pre-COVID-19 period was defined as April 1, 2019 to March 1, 2020, the time of the initial COVID-19 surge in Massachusetts. The period during COVID-19 was divided into two phases: 1) A COVID-19 surge period between March 1, 2020 and May 31, 2020 when lockdown measures were instituted in Massachusetts, and 2) the time following this initial COVID-19 surge defined as occurring from June 1, 2020 through November 30, 2020, when ambulatory services resumed albeit at lower capacity than prior to the pandemic.

2.3. Screening use

For patients who were eligible for each type of screening in each month, we determined whether s/he had received a USPSTF recommended screening test (mammogram for breast cancer, Pap test for cervical cancer, colonoscopy or FIT for colorectal cancer, or LDCT for lung cancer) based on their electronic health record.

2.4. Statistical analysis

Descriptive demographic characteristics were summarized at the individual level for each of the four screening cohorts. These variables included age, sex, race/ethnicity (White, Black, Latinx, Asian), highest education level (completed high school or less, college degree, graduate degree, unknown), and health insurance coverage (private, Medicare, Medicaid/uninsured).

We conducted an interrupted time-series analysis to evaluate the impact of the pandemic on screening rates by race/ethnicity (Bernal et al., 2017; Wagner et al., 2002). For each screening type, a separate Poisson generalized linear model was fit to analyze expected screening rates according to the specification:

$$\log E(Y_t) = \beta_0 + \beta_1T + \beta_2P_t + \beta_3T_P + \beta_4R_t + \beta_5R_T + \beta_6R_P + \beta_7R_P T + \beta_8R_P T_P + \beta_9T + \log(N_{ij}),$$

where $Y_{ij}$ and $N_{ij}$ denote the number of screenings and eligible patients in the t-th month and j-th racial/ethnic group, for $t = 0, 1, …, 19$ and $j = 0, 1, 2, 3$. Here $T_t = t$ is a linear trend that initiates from the beginning of the study period (April 2019), and $T_t = t – r$ is a linear trend initiating from pandemic onset time $r$ (March 2020). $P_t$ is an indicator of the pandemic period ($t \geq r$) and $R_t$ is a vector of 3 indicators for whether the j-th group corresponds to Black, Latinx, and Asian groups, relative to the White group. The $\beta_4$ and $\beta_5$ parameters estimate differences in mean screening rates, on the log scale, at the beginning of the study period and in their slope between racial/ethnic groups in the pre-pandemic period. The $\beta_6$ and $\beta_7$ parameters estimate how these disparities changed during the pandemic. We used two-sided Wald tests to test against the null hypotheses $\beta_4 = \beta_5 = 0$ (jointly for any minority race/ethnicity and separately for each race/ethnicity) to assess for the presence of any disparities relative to White individuals in the pre-pandemic period. We then assessed whether disparities have shifted during the pandemic by testing against $\beta_6 = \beta_7 = 0$. Finally, we tested whether expected screening rates, under the estimated model, in November 2020 differed from those in November 2019 based on testing for other linear restrictions on the coefficient parameters by Wald tests. Heteroskedasticity and autocorrelation consistent standard errors were used to
account for overdispersion and residual autocorrelation after modeling linear time trends (Donald, 1991; Zeileis, 2006). We also further stratified these regression analyses by known highest education level and insurance status to assess for potential differences in disparities across these sociodemographic subgroups. P-values were two-sided. Data management was done in SAS version X and data analysis was done in R version 4.0.2.

3. Results

Across eligible patients included in the analysis for any screening type, the mean age was 51.1 years (SD 15.9); mean age was youngest for those eligible for cervical cancer screening (46.8 years) and oldest for those eligible for lung cancer screening (65.7 years; Table 1). Overall, most patients were White (78.4%), followed by Black (8.4%), Asian (7.0%), and Latinx (6.2%). Most patients were female (59.4%), had a college degree (44.6%), and had private health insurance (67.3%). Similar trends in education and insurance were observed in patients eligible for breast, cervical and colon cancer screening. Among those eligible for lung cancer screening, there were fewer patients who were Asian (2.7%), had graduated from college (29.6%), or had private insurance (47.1%) than the other cancer screening populations.

At the beginning of the study period in April 2019, rates of mammography for breast cancer screening were lower for Asian compared to White women (incidence rate ratio (IRR) 0.82, 95% CI 0.74–0.91, p < 0.001; Table 2 and Fig. 1), as were rates of LDCT for Black and Latinx individuals compared to White individuals (IRR 0.59, 95% CI 0.40–0.88, p = 0.01; IRR 0.52, 95% CI 0.38–0.71, p < 0.001 respectively). In the pre-COVID-19 period, Latinx, Black and Asian individuals in aggregate had lower rates of screening compared to White individuals for breast (p < 0.001, “Overall” in Table 3 and lung cancer screening (p < 0.001). When specific race/ethnicities were compared to White individuals, Asian individuals also had lower rates of breast cancer screening (p < 0.001), while Latinx individuals had lower rates of lung cancer screening (p < 0.001). Expected screening rates plummeted for all cancer screening types and all racial/ethnic groups during the COVID-19 surge (March 2020 through May 2020), as shown in the Figure. This was followed by a period of recovery occurring at different rates for different racial/ethnic groups.

By November 2020 rates of breast, cervical and colorectal cancer screening overall were similar to screening rates prior to the pandemic in November 2019, and lung cancer screening rates significantly differed (“joint test” in Table 4). Specifically for Latinx individuals, rates of breast cancer screening by November 2020 were still lower than those in November 2019, and rates of lung cancer screening were higher. (Table 4 and Figure). For both Black and White individuals, lung cancer screening rates were also higher by November 2020 than they had been in November 2019. As screening rates began to recover following the COVID surge, there were no significant changes in disparities ascertained in the pre-COVID-19 period after the onset of the pandemic (p = 0.26 for breast, p = 0.71 for cervical, p = 0.89 for CRC, p = 0.34 for lung; Table 2). There were similarly no clear changes in disparities by race/ethnicity after stratification by education level and insurance (data not shown).

4. Discussion

Our findings support prior work that demonstrates that cancer screening rates plummeted at the start of the pandemic (Kaufman et al., 2020; Mast and Munoz del Rio, 2020; Corley et al., 2020). This work extends what is known about the effect of the pandemic on cancer screening in the US by specifically looking at the trajectory of disparities in cancer screening early in the pandemic and showed no significant worsening or improvement in racial/ethnic disparities early in the initial COVID-19 recovery period compared to prior to the pandemic. Yet, racial/ethnic disparities in cancer screening present prior to the pandemic were still observed after the COVID-19 pandemic began.

While prior work suggests that other crises that have disrupted cancer screening may ultimately result in delays in cancer diagnosis (El Saghir et al., 2018), our work is unique in examining the effect of a catastrophic disruption in care on disparities. Kanjanvaikoon et al. showed that women diagnosed with cervical cancer had higher stage of disease among those diagnosed with cancer after Hurricane Katrina in 2005, likely due to a decrease in cervical screening utilization (Kanjanvaikoon et al., 2011). Preliminary estimates from pandemic-associated disruptions in national cancer screening programs in the Netherlands and the United Kingdom also raise concern for delays in cancer diagnoses and their effect on mortality (Dimohamed et al., 2020; Marneg et al., 2020).

The pandemic has brought renewed attention to disparities in health and health care in the US. As health care systems and public health departments will face financial stresses and the ongoing challenges of COVID-19 interventions should be considered to prevent or improve disparities in cancer screening to thwart any ultimate worsening of the disparities in health that have contributed to the adverse impact and outcomes of the pandemic (Wen and Sadeghi, 2020). As we move forward, the following considerations merit further discussion: 1) Whether COVID-19 related financial stresses on healthcare systems allow equal resumption of robust screening programs across the population; 2) Whether shifts to telemedicine will generate differences in who will request or be referred for screening, who will receive and complete active outreach, or who will schedule in-person follow-up testing; 3) Whether the pandemic’s economic ramifications will exacerbate existing national sociodemographic differences in healthcare access and outcomes; 4) Whether differences in vaccine uptake or concerns about the possibility of health care associated exposure to coronavirus will result in differential return to screening and other preventive services over time by race/ethnic groups; 5) Whether having insurance coverage will lead to preferential resumption of cancer screening. The resumption of routine healthcare, including cancer screening, must incorporate intentional strategies to monitor for and minimize health disparities.

Although our study did not show worsened disparities in cancer

---

Table 1

| Cancer screening type | Breast | Cervical | Colon | Lung |
|-----------------------|--------|----------|-------|------|
| N                     | 29,081 | 51,436   | 24,706| 10,697|
| Age (mean) (SD)       | 55.1 (10.6) | 46.8 (12.8) | 59.5 (8.0) | 64.7 (6.6) |
| Female                | –      | –        | 14,913| 5248 |
| Race                  |        |          |       |      |
| White, non-Latinx     | 21,707 | 38,775   | 19,746| 8926 |
| Black, non-Latinx     | 3116 (10.7) | 4911 (9.6) | 2167 (8.8) | 955 (8.9) |
| Latinx                | 1981 (6.8) | 3511 (6.8) | 1279 (5.2) | 524 (4.9) |
| Asian, non-Latinx     | 2277 (7.8) | 4239 (8.2) | 1514 (6.1) | 292 (2.7) |
| Education             |        |          |       |      |
| High school or less   | 7745 (26.6) | 12,934 | 7270 (29.4) | 4671 |
| College degree        | 12,984 | 24,151   | 10,247| 3169 |
| Graduate degree       | 3075 (10.6) | 6022 (11.7) | 2551 (10.3) | 725 (6.8) |
| Unknown               | 5277 (18.1) | 8329 (16.2) | 4638 (18.8) | 2132 |
| Health insurance      |        |          |       |      |
| Private               | 18,696 | 38,780   | 15,602| 5037 |
| Medicare              | 5360 (18.4) | 3616 (7.0) | 5508 (22.3) | 1099 |
| Medicaid/no insurance | 5025 (17.3) | 9040 (17.6) | 3596 (14.6) | 1561 |

---

F.O. Marcondes et al. Preventive Medicine 151 (2021) 106640

[Donald, 1991; Zeileis, 2006]
Table 2
Poisson generalized linear model coefficient estimates.

|             | Breast |          |          | Cervical |          |          | Colon |          |          | Lung |          |          |          |
|-------------|--------|----------|----------|----------|----------|----------|-------|----------|----------|------|----------|----------|----------|
|             | IRR$^a$ | 95% CI   | P-value  | IRR$^a$ | 95% CI   | P-value  | IRR$^a$ | 95% CI   | P-value  | IRR$^a$ | 95% CI   | P-value  | IRR$^a$ | 95% CI   | P-value  |
| **Time (month)**$^b$ | 0.99   | 0.97     | 1.00     | 0.32     | 1.00     | 0.98     | 1.02   | 0.94     |          | 0.96   | 0.95     | 0.98     | <0.001   | 0.98     | 0.96     | 1.01     | 0.22   |
| **Before-after pandemic onset**$^c$ |          |          |          |          |          |          | 0.21   | 0.08     | 0.57     | 0.002   | 0.22     | 0.09     | 0.53     | <0.001   | 0.26     | 0.09     | 0.79     | 0.02     | 0.54   | 0.33     | 0.89     | 0.02   |
| LatinX (ref: White) | 0.85   | 0.66     | 1.08     | 0.17     | 1.12     | 0.98     | 1.28   | 0.10     |          | 0.77   | 0.59     | 1.01     | 0.05     | 0.52     | 0.38     | 0.71     | <0.001  |
| Asian | 0.82   | 0.74     | 0.91     | <0.001   | 0.99     | 0.82     | 1.20   | 0.91     |          | 1.06   | 0.80     | 1.39     | 0.70     | 1.15     | 0.75     | 1.77     | 0.52   |
| Black | 0.99   | 0.86     | 1.14     | 0.84     | 1.03     | 0.90     | 1.17   | 0.69     |          | 1.03   | 0.85     | 1.24     | 0.78     | 0.59     | 0.40     | 0.88     | 0.01   |
| Time*onset | 1.24   | 1.06     | 1.44     | 0.01     | 1.23     | 1.07     | 1.42   | 0.004    |          | 1.23   | 1.03     | 1.46     | 0.02     | 1.15     | 1.03     | 1.25     | 0.001  |
| Time*LatinX | 1.01   | 0.96     | 1.06     | 0.72     | 0.98     | 0.96     | 1.01   | 0.14     |          | 1.03   | 0.99     | 1.07     | 0.19     | 1.01     | 0.95     | 1.09     | 0.72   |
| Time*Asian | 1.00   | 0.98     | 1.02     | 0.89     | 0.99     | 0.97     | 1.02   | 0.61     |          | 0.99   | 0.94     | 1.03     | 0.55     | 0.95     | 0.88     | 1.01     | 0.11   |
| Time*Black | 0.98   | 0.94     | 1.02     | 0.24     | 0.99     | 0.96     | 1.01   | 0.20     |          | 0.99   | 0.96     | 1.02     | 0.51     | 1.06     | 1.00     | 1.11     | 0.05   |
| Onset*LatinX | 0.71   | 0.15     | 3.35     | 0.67     | 0.98     | 0.25     | 3.5    | 0.973    |          | 0.99   | 0.11     | 9.10     | 0.99     | 0.90     | 0.37     | 2.19     | 0.82   |
| Onset*Asian | 0.87   | 0.27     | 2.81     | 0.81     | 0.98     | 0.44     | 2.21   | 0.97     |          | 1.00   | 0.2     | 5.02     | 1.00     | 0.32     | 0.07     | 1.54     | 0.15   |
| Onset*Black | 0.98   | 0.51     | 1.89     | 0.95     | 0.94     | 0.57     | 1.56   | 0.81     |          | 0.69   | 0.22     | 2.17     | 0.53     | 1.01     | 0.60     | 1.67     | 0.99   |
| Time*onset*LatinX | 0.97   | 0.77     | 1.22     | 0.78     | 1.03     | 0.82     | 1.30   | 0.78     |          | 0.97   | 0.67     | 1.39     | 0.85     | 1.00     | 0.88     | 1.13     | 0.97   |
| Time*onset*Asian | 0.97   | 0.81     | 1.16     | 0.75     | 1.0     | 0.86     | 1.16   | 0.98     |          | 1.01   | 0.79     | 1.30     | 0.94     | 1.24     | 0.98     | 1.58     | 0.08   |
| Time*onset*Black | 1.02   | 0.92     | 1.13     | 0.69     | 1.03     | 0.95     | 1.13   | 0.42     |          | 1.07   | 0.90     | 1.27     | 0.44     | 0.94     | 0.86     | 1.03     | 0.17   |

Test for changes in disparities

|             | 0.26   |          | 0.71     |          | 0.89     |          | 0.34   |          |

$p$-values from Wald test for hypothesis $\beta_6 = \beta_7 = 0$.

$^a$ IRR = incidence rate ratio; CI = confidence interval.

$^b$ Time refers to linear trend in months (IRR refers to rate ratio for each month relative to prior).

$^c$ Onset refers to before or after onset of the COVID-19 pandemic defined as March 2020.

Fig 1. Expected screening rates estimated by the Poisson model over time by race/ethnicity, separately for each cancer type.

NOTES: Solid point represents raw monthly screening rates by race. Separate Poisson generalized linear models are fit for each screening type.
COVID-19 cancer screening inequities. Our results nevertheless indicated that in many cases disparities were maintained as screening exams resumed and the rates of recovery were uneven across different race/ethnicities. It remains to be seen whether these differences will worsen as the pandemic continues and eventually subsides. Worsened disparities in cancer screening are likely to result in delayed cancer detection, more advanced stages of malignancy at diagnosis, and loss of life-years among those with cancer.

Our study is not without limitations. Our study is restricted to individuals with a primary care provider at a large academic health system in one region of the United States, with few disparities in access to care prior to the pandemic. As a result, there may be selection effects that make it difficult to generalize the results to other patient populations. Due to the limited number of screenings observed each month within racial/ethnic groups by cancer type, this study may have limited power to detect subtle shifts in disparities after the onset of the pandemic. This analysis is also restricted to time periods covering the first surge and subsequent recovery. Further studies are needed to investigate the cancer diagnoses/cancer stage migration due to delays in screening as the COVID-19 pandemic evolves.

The pandemic has documented the necessity of countering racial/ethnic disparities in care and provides opportunity for innovative cancer screening strategies including FIT testing and fecal DNA testing for colorectal cancer screening and potentially self-sampling HPV testing for cervical cancer screening. Real-time data monitoring of trends in screening and other preventive care by race/ethnicity should be considered to mitigate the challenge of resuming cancer screening during the pandemic without worsening disparities.

Declaration of Competing Interest

None of the authors have any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work.

Acknowledgments

This study was conducted as part of the National Cancer Institute (NCI)-funded consortium, METRICS (Multi-level Optimization of the Cervical Cancer Screening Process in Diverse Settings & Populations; Grant number 1UM1CA221940).

Table 3

| Cancer Group |IRR point estimates|p-value|
|--------------|------------------|--------|
|               | Race vs. White IRR estimates refer to rates of screening in April 2019 |        |
|               | Time* race interaction refer to the ratio of year-to-year OR for each race relative to white |        |

Table 4

| Cancer Group |Ro 2019 rate|Ro 2020 rate|IRR|p-value|
|--------------|------------|------------|----|--------|
|               |Race IRR estimates refer to rates of screening in April 2019 |        |
|               |Time* race interaction refer to the ratio of year-to-year OR for each race relative to white |        |

References

Bernal, J.L., Cummins, S., Gasparini, A., 2017. Interrupted time series regression for the evaluation of public health interventions: a tutorial. Int. J. Epidemiol. 46 (1), 348–355.

Beydoun, H.A., Beydoun, M.A., 2007. Predictors of colorectal cancer screening behaviors among average-risk older adults in the United States. Cancer Causes Control 19 (4), 339–359.

Chatterjee, S., Gupta, D., Caputo, T.A., Holcomb, K., 2016. Disparities in gynecological malignancies. Front. Oncol. 6, 36.

Gold, J.A.W., Wong, K.K., Szablewski, C.M., et al., 2020. Characteristics and clinical outcomes of adult patients hospitalized with COVID-19 - Georgia, march 2020. MMWR. 69 (18), 545–550.

Hall, I.J., Tangka, F.K.L., Sabatino, S.A., Thompson, T.D., Graubard, B.I., 2018. Patterns and trends in cancer screening in the United States. Prev. Chronic Dis. 15, 1–59.

Kanjivaiwook, P., Gerber, D., Robinson, W.R., 2011. Long term impact of natural disaster on cervical cancer demographics. Gynecol. Oncol. 123 (2), 446.

Koopman, W.H., Chen, Z., Niles, J., Pesko, Y., 2020. Changes in the number of US patients with newly identified cancer before and during the coronavirus disease 2019 (COVID-19) pandemic. JAMA Netw. Open 3 (8), e2017267.

Kreps, S., Prasad, S., Brownstein, J.S., et al., 2020. Factors associated with US adults’ likelihood of accepting COVID-19 vaccination. JAMA Netw. Open 3 (10), e2025594.

Man, R.X.-G., Lack, D.A., Wyatt, C.E., Murray, V., 2018. The effect of natural disasters on cancer care: a systematic review. Lancet Oncol. 19 (9), e482–e499.
Maringe, C., Spicer, J., Morris, M., et al., 2020. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol. 21 (8), 1023–1034.

Mast, C., Munoz del Rio, A., 2020. Delayed Cancer Screenings—A Second Look. https://ehrn.org/articles/delayed-cancer-screenings-a-second-look/.

Miller, M.J., Xu, L., Qin, J., et al., 2021. Impact of COVID-19 on cervical cancer screening rates among women aged 21–65 years in a large integrated health care system—Southern California, January 1–September 30, 2019, and January 1–September 30, 2020. MMWR. 70 (4), 109–113.

Moyer, V.A., 2014. Screening for lung cancer: U.S. Preventive Services task force recommendation statement. Ann. Intern. Med. 160 (5), 330–338.

Musselwhite, L.W., Oliveira, C.M., Kwaramba, T., et al., 2016. Racial/ethnic disparities in cervical cancer screening and outcomes. Acta Cytol. 60 (6), 518–526.

National Center for Health Statistics, 2019. Table 33. Use of mammography among women aged 40 and over, by selected characteristics: United States, selected years 1987–2015.

Nelson, R.L., Dolezar, T., Freels, S., Persky, V., 1997. The relation of age, race, and gender to the subsite location of colorectal carcinoma. Cancer. 80 (2), 193–197.

Price-Haywood, E.G., Burton, J., Fort, D., Seoane, L., 2020. Hospitalization and mortality among black patients and White patients with Covid-19. NEJM. 382 (26), 2534–2543.

Screening for Colorectal Cancer, 2008. U.S. Preventive Services task force recommendation statement. Ann. Intern. Med. 149 (9), 627–637.

Siu, A.L., 2016. Screening for breast cancer: U.S. Preventive Services task force recommendation statement. Ann. Intern. Med. 164 (4), 279–296.

U.S. Cancer Statistics Working Group, 2017. U.S. Cancer Statistics Data Visualizations Tool, based on 2019 Submission data (1999–2017). U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. www.cdc.gov/cancer/dataviz, released in June 2020. 2017.

Wagner, A.K., Soumerai, S.B., Zhang, F., Ross-Degnan, D., 2002. Segmented regression analysis of interrupted time series studies in medication use research. J. Clin. Pharm. Ther. 27 (4), 299–309.

Wen, L.S., Sadeghi, N.B., 2020. Addressing racial health disparities in the COVID-19 pandemic: immediate and long-term policy solutions. Health Affairs Blog.

White, A., Thompson, T.D., White, M.C., et al., 2017. Cancer screening test use—United States, 2015. MMWR. 66 (8), 201–206.

Zeileis, A., 2006. Object-oriented computation of sandwich estimators. J. Stat. Softw. 16 (9), 1–16.